Business Wire

CA-AGENDIA

10.12.2020 22:32:11 CET | Business Wire | Press release

Share
Agendia Spotlight Poster at SABCS 2020 Confirms Pre-Operative Utility of MammaPrint® and BluePrint®

Agendia, Inc., a world leader in precision oncology for breast cancer, announced new 5-year data from the NBRST trial that will be presented in a poster spotlight discussion Thursday, December 10, 2020 from 3:30pm-4:45pm CST at the 2020 San Antonio Breast Cancer Symposium (SABCS 2020).

The poster, entitled 5-year outcomes in the NBRST trial: Preoperative MammaPrint ® and BluePrint ® breast cancer subtype is associated with neoadjuvant treatment response and survival , contains the largest data set evaluating a genomic test in the neoadjuvant setting with long-term outcomes. These outcomes demonstrate the predictive and prognostic abilities of MammaPrint® and BluePrint® , and underpin both assays’ pre-operative utility.

In the 5-year results of the Neoadjuvant Breast Symphony Trial (NBRST), 22% of the tumors evaluated were reclassified from their original clinical subtype into a different molecular subtype by MammaPrint and BluePrint. This reclassification has significant implications for treatment planning, reinforcing the importance of the multi-disciplinary care team having this meaningful information at the earliest point after diagnosis to inform the decision for the timing of surgery and systemic therapy.

Importantly, the reclassification by BluePrint allowed researchers to detect more genomic diversity within pathologically ER+ and HER2 negative breast cancers than previously thought. 18% of those tumors were reclassified as Basal-Type by BluePrint (ER+/Basal) while 44% of pathologically HER2+ tumors were reclassified as Luminal- or Basal-Type by BluePrint. Of note, the response to treatment and longer term outcomes in those reclassified patients were distinctly different and aligned with the subtype identified by BluePrint.

“Genomic classification is uncovering the diversity in these pathologically-defined subsets,” said Pat Whitworth, M.D., first author of the spotlight poster and a breast surgical oncologist at the Nashville Breast Center. “If a conventional HER2+ or an ER+/HER2 negative tumor is reclassified as BluePrint Basal-Type, switching to a different treatment approach, such as a HER2-targeted regimen with optimal basal coverage or different timing for surgery, may improve outcomes for those patients. With this extra layer of information, the patient and her care team are able to make important decisions at the very beginning of their journey that will be felt years down the line. Just as important, these patients should be the focus of upcoming trials.”

In looking into the genomic makeup of the tumors, BluePrint could further stratify ER+ and HER2+ breast cancers as Luminal- or Basal-Type, which respond differently to treatment and could one day impact how these patients are treated. This observation echoes what was seen in a subanalysis of the APHINITY trial, also part of a spotlight poster discussion at SABCS 2020.

“The finding that a subset of ER+ HER2 negative primary breast cancers has a basal genotype on BluePrint analysis is a novel and very provocative result that compels us to study this further,” said Joyce O’Shaughnessy, M.D., Director of the Breast Cancer Research Program for Texas Oncology and the US Oncology Network. “Should the ER+/basal breast cancers be treated as triple negative breast cancers, with platinum-based regimens, capecitabine post-op for residual disease and potentially with preop checkpoint inhibitors? We plan to study preop administration of platinum-based chemotherapy in patients with ER+/basal cancer to determine whether their outcomes parallel those of triple negative basal breast cancers.”

Also presented at SABCS 2020 is a supporting poster on the NBRST study, “Molecular subtyping by BluePrint improves prediction of treatment responses and survival outcomes in patients with discordant clinical and genomic classification ,” which focused on the discordant groups within the 22% of BluePrint reclassifications displayed in the NBRST study. The data showed that molecular subtyping using MammaPrint and BluePrint is additive to pathologic assessment and thus facilitates more informed treatment decisions.

In addition, the supplemental NBRST poster reinforces the importance of genomic testing to further stratify Luminal patients. The data showed that Luminal A-Type patients have excellent outcomes on neoadjuvant endocrine therapy alone, an important consideration during the COVID-19 pandemic, while Luminal B-Type patients need additional systemic treatment.

According to James Pellicane, M.D., Director of Breast Oncology at the Bon Secours Cancer Institute, “These data confirm that BluePrint can be utilized as a tool to determine whether neoadjuvant systemic therapy or surgery followed by adjuvant therapy is the best option for a patient based on the molecular subtype of their breast cancer and its predicted response to therapy. What we’ve seen from NBRST is that certain patients, specifically the Luminal A subtypes, will respond to neoadjuvant endocrine therapy and have good long-term outcomes postoperatively with endocrine therapy alone. Others may respond to neoadjuvant endocrine therapy but because of their more aggressive biology, specifically the Luminal B subtypes, will benefit from cytotoxic chemotherapy in the adjuvant or sometimes in the neoadjuvant setting. As a surgeon, it’s comforting to know that you can triage these patients more effectively, having a better understanding of the biology of their breast cancer and how it will respond to different treatment algorithms and how that response corresponds with their long-term outcome.”

These data are part of a large suite of 13 posters, spotlight sessions and an oral presentation on MammaPrint and BluePrint that were accepted to SABCS 2020, and underscore Agendia’s mission to help guide the diagnosis and personalized treatment of breast cancer for all patients throughout their treatment journey.

About Agendia

Agendia is a precision oncology company headquartered in Irvine, California, committed to bringing early stage breast cancer patients and their physicians the information they need to make the best decisions for the full treatment journey. The company currently offers two commercially-available genomic profiling tests, supported by the highest levels of clinical and real world evidence, that provide comprehensive genomic information that can be used to identify the most effective breast cancer treatment possible for each patient.

MammaPrint® , the 70-gene breast cancer recurrence assay, is the only FDA-cleared risk of recurrence test backed by peer-reviewed, prospective outcome data and inclusion in both national and international treatment guidelines. BluePrint® , the 80-gene molecular subtyping assay, is the only commercially-available test that evaluates the underlying biology of a tumor to determine what is driving its growth. Together, MammaPrint® and BluePrint® provide a comprehensive genomic profile to help physicians make more informed decisions in the pre- and post-operative treatment settings.

Agendia develops evidence-based novel genomic tests and forges partnerships with groundbreaking companies to develop next-generation digital treatment tools. The ongoing research builds an arsenal of data that improve patient outcomes and support the evolving clinical needs of breast cancer patients and their physicians every step of the way, from initial diagnosis to cancer-free.

Agendia’s assays can be ordered on core biopsies or surgical specimens to inform pre- and post-operative treatment decisions. For more information on Agendia’s assays and ongoing trials, please visit www.agendia.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

NetJets Becomes Official Private Aviation Provider of the Hahnenkamm Races in Kitzbühel20.11.2026 18:45:00 CET | Press release

The Partnership brings together two brands committed to excellence, precision and exceptional experiences NetJets, the global leader in private aviation, is delighted to announce its newest partnership with the Hahnenkamm Races in Kitzbühel, Austria, becoming the event's Official Private Aviation Provider. The Hahnenkamm Races are among the most prestigious and celebrated events in world alpine skiing. They attract athletes, business leaders, international guests and winter sports enthusiasts from around the world. Through this partnership, NetJets and the Hahnenkamm Races are aligning two brands renowned for excellence, precision and world-class experiences. The partnership is an exciting addition to NetJets' growing portfolio of premium lifestyle and sporting partnerships, offering Owners unique opportunities to access one of Europe's most iconic winter sporting events. Alongside premium hospitality and unforgettable behind-the-scenes experiences, the collaboration will help create e

Frontgrade Technologies Help Power Critical Computing and Electronics Aboard NASA’s Roman Space Telescope20.11.2026 18:40:00 CET | Press release

Frontgrade processors and radiation-hardened microelectronics support critical spacecraft and instrument functions on NASA’s flagship astrophysics mission Frontgrade today announced that technologies from across its space electronics portfolio are supporting multiple mission-critical systems aboard NASA’s Nancy Grace Roman Space Telescope, which successfully launched on August 30, 2026. Roman is NASA’s flagship astrophysics observatory designed to investigate dark energy, discover exoplanets and explore the evolution of the universe. Its onboard electronics include radiation-hardened processors and microelectronics, providing critical processing, communications, power-management and control functions across the spacecraft. At the centre of Roman’s computing architecture are Frontgrade Gaisler’s GR740 and GR712RC processors. The GR740 radiation-hardened quad-core LEON4FT processor serves as the computing engine for the Wildcat Processor Card, used in the spacecraft’s primary and redunda

Inside Moutai House Singapore: Beyond Baijiu, A Cultural Encounter20.11.2026 16:05:00 CET | Press release

On November 13, Moutai House officially opened at Fullerton Waterboat House in Singapore. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261120301288/en/ On November 13, Moutai House officially opened at Fullerton Waterboat House in Singapore. As the world’s first Moutai brand experience space built under its new SI standards, this three-storey venue brings together cultural exhibitions, baijiu tasting, distinctive dining and creative cocktails. Using Moutai as a bridge, it creates new opportunities for Chinese baijiu culture to blend with and draw inspiration from Singapore’s diverse lifestyle and cultural scene. As early as 1954, Guizhou Moutai arrived in Singapore via the Singapore River, marking its first entry into Southeast Asia, right across from Fullerton Waterboat House. 72 years later, Moutai House has found its home along the same riverbank, transforming a historic arrival into a lasting presence and turning a con

ViTAA Medical and The Society for Vascular Surgery Announce Strategic Partnership20.11.2026 15:00:00 CET | Press release

ViTAA Medical to Become Key SVS AI Partner, Advancing AI Education and Responsible Adoption in Vascular Care ViTAA Medical Solutions Inc. (ViTAA) today announced a strategic partnership with The Society for Vascular Surgery (SVS) to advance evidence, education, and the responsible adoption of quantitative imaging and artificial intelligence in vascular care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261120954362/en/ The partnership will support evidence building, best practices, educational resources for SVS members, physicians and trainees on AI validation, interpretation, and clinical limitations. The relationship has the potential to pave the way for additional AI tools and resources for SVS members through the Society in the future. The partnership creates a framework for the organizations to lead AI-enabled research opportunities involving imaging and clinical outcomes. Mitchel Benovoy, PhD, Chief Executive Officer

Epitech Group and Horus Pharma sign a global licensing agreement to develop adelmidrol in eye health20.11.2026 14:39:00 CET | Press release

Epitech Group S.p.A., an Italian biopharmaceutical firm specializing in neuro-inflammation, and Horus Pharma, a French laboratory specializing in ophthalmology, announce a global licensing agreement for adelmidrol, a molecule belonging to the ALIAmide family, developed by Epitech Group. This agreement grants Horus Pharma exclusive rights to develop and market adelmidrol for human ophthalmology and periocular dermatology applications. It aims to explore new approaches to address unmet medical needs in eye health. A combination of complementary scientific expertise Epitech Group has been studying ALIAmides and their role in physiological regulatory mechanisms for over 30 years, building on the research of Rita Levi-Montalcini, the 1986 Nobel Prize in Medicine laureate who first identified the ALIA mechanism. Horus Pharma, for its part, contributes over 20 years of ophthalmology expertise, strong R&D capabilities, and its international presence. Against the backdrop of an aging population

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye